Bioject Medical Technologies (Portland, Oregon), a developer of needle-free drug delivery systems, reported receiving a Nasdaq notification that it has failed to comply with the minimum bid price requirement for continued listing because for 30 consecutive business days, the bid price of Bioject’s common stock has closed below the minimum $1 bid requirement. Bioject has been provided until April 2, 2007, to regain compliance with the requirement.
“By executing on our business strategy in the near future, we believe our stock price will rise above the $1 minimum and we will be in compliance,” said Jim O’Shea, president/CEO and chairman of Bioject. “We are also assessing what other actions we may need to take to regain compliance with the minimum bid requirement.”
Bioject manufactures needle-free drug delivery systems that work by forcing medication at high speed through a tiny orifice held against the skin.
Cleveland hosts two medical summits
Cleveland Clinic (Cleveland, Ohio) willhost two summits this fall focused on medical innovation and emerging trends in the fields of cardiovascular disease and neurosciences. Both will take place at the InterContinental Hotel & MBNA Conference Center:
• Oct. 20-22: Cleveland Clinic’s Kaufman Center for Heart Failure and the Association for Thoracic Surgery will host a national summit, “21st Century of Heart Failure: Synchronizing Surgical and Medical Therapies for Better Outcomes.” The conference is expected to draw more than 450 physicians and researchers to discuss the latest trends for the treatment of end-stage heart failure. Highlights will include early results of a European trial using a new cardiac preservation system in the area of cardiac transplantation, and a session focused on contemporary clinical experience with 10 new heart pumps.
• Nov. 6-8: the fourth annual Cleveland Clinic Medical Innovation Summit is expected to draw more than 800 industry executives, entrepreneurs, venture capitalists and clinicians who will focus on the medical, technological and economic trends reshaping the neuroscience market. Also featured will be the clinic’s first selection of the “Top 10” healthcare innovations, live, interactive surgeries and in-depth debates on industry challenges.
Cleveland Clinic is a leader in diagnosis and treatment of cardiovascular disease.
• Roche Diagnostics (Indianapolis) reported that its Accu-Chek Spirit insulin pump system is now available in the U.S. This diabetes self-management system includes an insulin pump, a blood glucose monitor and software with a bolus calculator for monitoring, analysis and insulin delivery. Features such as three operating menus, four bolus options and five basal rate profiles make insulin pump therapy more flexible and convenient for people with diabetes, said Roche. Roche makes insulin pump therapy systems and supplies.
• BioLucent (Aliso Viejo, California) reported the availability of a new cushion for use with the Dilon 6800 Gamma Camera, sized to fit the surface of the Dilon equipment. Dilon Technologies (Newport News, Virginia)manufactures the Dilon 6800 Gamma Camera for use during Breast-Specific Gamma Imaging (BSGI). BSGI is an adjunct diagnostic procedure to mammography where the breast is immobilized for 6-10 minutes per view. MammoPad can be used to cushion the detector as well as the shield. The cushion is made of a radiolucent material that does not interfere with imaging of the breast and has a grip-like effect that helps stabilize the breast during longer duration imaging necessary for BSGI.
• Bioject Medical Technologies (Portland, Oregon) reported that studies presented at the Modern Vaccine Adjuvants and Delivery Systems Conference and at the AIDS Vaccine Conference 2006 show improved immunogenicity of vaccines when used with the Biojector 2000 (B2000) in cancer and AIDS vaccines. The presentation, titled “DNA immunization against tumor antigens using the B2000, a needle free injection device, in preclinical mouse model,” showed how the B2000 improved expression, thus making the vaccine more effective. The B2000 is being used in clinical trials for the melanoma vaccines as well as other vaccines being developed by Memorial Sloan-Kettering. Bioject develops needle-free drug delivery systems.
• CardioVascular Technologies (Palo Alto, California) has received a Notice of Allowance for its patent application, titled “Vascular Couplers, Techniques, Methods, and Accessories.” The coupler system enables clampless coronary artery bypass graft (CABG) surgery, minimizing aortic manipulation and embolic dislodgement by not requiring cross-clamping or aortic side-biting during the procedure. By not utilizing a clamp on the aorta, the system is designed to reduce the incidence of postoperative cognitive dysfunction (POCD), which occurs in up to about 50% of patients undergoing CABG procedures. The sutureless vascular coupler system can be used during cardiopulmonary supported procedures, as well as off-pump/beating heart, minimally invasive direct coronary artery bypass (MIDCAB), endoscopic or robotically assisted surgical procedures. CardioVascular Technologies develops biomedical devices, specializing in surgical and catheter-based technologies.